Cellergy Therapeutics Ltd. is an Israeli biotechnology startup based in Yavne, Israel. Israeli company records list it as incorporated on May 24, 2021, while some company-facing profiles describe it as founded in 2022.

The company was co-founded by Rachel Diamant, Dr. David Baram and Dr. Todd Wider. Diamant serves as CEO, while Baram is co-founder and chairman of the board. Baram previously co-founded Emendo Biotherapeutics, which was acquired in a deal valued at about $300 million.

Cellergy is a small, privately held company with roughly fewer than 10 employees. Its research operations are in Yavne, around 20 km south of Tel Aviv.

Its main focus is mitochondrial transplantation therapy. The company is developing ways to isolate healthy mitochondria from donor cells and deliver them as a treatment for diseases linked to poor cellular energy production.